Clinical Trials Logo
  1. Home
  2. Metastatic Disease
  3. NCT01703910

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Metastatic Disease Clinical Trial

Official title:
Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.

Clinical Trial Summary

The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of chemosensitivity by comprehensive genetic expression analysis from tumor samples.

Clinical Trial Description

It is a prospective, randomized study in patients with metastatic colorectal carcinoma progressing after two lines of prior therapy. Patients will be randomized (1:1) to receive chemotherapy as determined by its oncologist or treatment according to chemosensitivity profile obtained. For obtaining the profile a histological tumor sample and a sample of venous blood in a tube with heparin standard are necessary . This latter sample will be processed to isolate circulating tumor cells by cell adhesion with matrix coated glass spheres. The RNA from these circulating tumor cells as well as from tumor cells of tumor biopsies from the same patients will be extracted by a standard procedure for extracting RNA for genetic expression analysis. Based on the analysis performed on tumor biopsy is generated a ranked list of potentially more effective treatments in every case ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01703910
Study type Interventional
Source Centro Nacional de Investigaciones Oncologicas CARLOS III
Contact
Status Completed
Phase Phase 2
Start date November 2012
Completion date December 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Terminated NCT04116164 - Safety and Targeting of Anti-hk2 Antibody in mCRPC Early Phase 1
Active, not recruiting NCT04595032 - MAnagement of METastatic Disease In Campania (MAMETIC)
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Withdrawn NCT02496832 - A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo N/A
Completed NCT01763970 - Stereotactic Radiation Therapy for Pediatric Sarcomas N/A
Completed NCT00609401 - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) Phase 2
Completed NCT02628379 - Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Completed NCT00480389 - Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal Phase 2
Recruiting NCT03632005 - Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery N/A
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Terminated NCT02175654 - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab Phase 2
Not yet recruiting NCT01861938 - Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Phase 2/Phase 3
Completed NCT01875380 - Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT00532454 - Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen Phase 2
Terminated NCT02795819 - Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Phase 1
Recruiting NCT05188911 - Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Completed NCT03823989 - Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients Phase 1
Terminated NCT01904916 - CPCT-05 Biopsy Protocol Patient Selection N/A
Terminated NCT01484860 - Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase 2